Perkins Coie Trust Co increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 99.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,537 shares of the medical research company’s stock after purchasing an additional 1,267 shares during the period. Perkins Coie Trust Co’s holdings in Amgen were worth $437,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Jackson Grant Investment Advisers Inc. lifted its holdings in Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares in the last quarter. Conservest Capital Advisors Inc. lifted its holdings in Amgen by 0.4% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after purchasing an additional 13 shares in the last quarter. M Holdings Securities Inc. lifted its holdings in Amgen by 0.6% in the 1st quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after purchasing an additional 18 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in Amgen by 1.2% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,223 shares of the medical research company’s stock worth $529,000 after purchasing an additional 38 shares in the last quarter. Finally, AMG Funds LLC lifted its holdings in Amgen by 0.4% in the 1st quarter. AMG Funds LLC now owns 10,089 shares of the medical research company’s stock worth $1,655,000 after purchasing an additional 41 shares in the last quarter. 78.09% of the stock is currently owned by institutional investors.

A number of research analysts recently commented on AMGN shares. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a report on Monday, June 5th. Sanford C. Bernstein set a $164.00 price target on Amgen and gave the stock a “hold” rating in a report on Thursday, June 8th. Morgan Stanley boosted their price target on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th. Finally, UBS AG reissued a “neutral” rating and issued a $175.00 price target (up from $174.00) on shares of Amgen in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average target price of $186.14.

TRADEMARK VIOLATION NOTICE: “Amgen Inc. (AMGN) Shares Bought by Perkins Coie Trust Co” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/21/amgen-inc-amgn-shares-bought-by-perkins-coie-trust-co.html.

Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.25% during trading on Thursday, reaching $187.70. The company’s stock had a trading volume of 753,141 shares. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a market capitalization of $136.96 billion, a PE ratio of 17.10 and a beta of 1.35. The stock has a 50 day moving average of $175.99 and a 200-day moving average of $169.31.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter last year, the business posted $2.84 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.44%. Amgen’s payout ratio is 41.93%.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.